The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
Alzheimer's disease (AD) is characterized by deposition of amyloid-β (Aβ) plaques and neurofibrillary tangles in the brain, accompanied by synaptic dysfunction and neurodegeneration. Antibody-based immunotherapy against Aβ to trigger its clearance or mitigate its neurotoxicity has so far been unsuccessful. Here we report the generation of aducanumab, a human monoclonal antibody that selectively targets aggregated Aβ. In a transgenic mouse model of AD, aducanumab is shown to enter the brain, bind parenchymal Aβ, and reduce soluble and insoluble Aβ in a dose-dependent manner. In patients with prodromal or mild AD, one year of monthly intravenous infusions of aducanumab reduces brain Aβ in a dose- and time-dependent manner. This is accompanied by a slowing of clinical decline measured by Clinical Dementia Rating-Sum of Boxes and Mini Mental State Examination scores. The main safety and tolerability findings are amyloid-related imaging abnormalities. These results justify further development of aducanumab for the treatment of AD. Should the slowing of clinical decline be confirmed in ongoing phase 3 clinical trials, it would provide compelling support for the amyloid hypothesis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Aducanumab (1) binds to 3-7 amino acids of Aβ, targeting soluble oligomers and insoluble fibrils.418,419”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [418]
In the citing paper
“Aducanumab has been tested in a phase II study, demonstrating its biological effect in terms of Aβ removal via PET with amyloid tracer [56].”
From Treatment of Alzheimer’s Disease: Beyond Symptomatic Therapies (2023) · cites this paper as [56]
In the citing paper
“Additionally, amyloid was cleared from the six cortical regions of interest, namely the frontal, parietal, lateral temporal, sensorimotor, anterior, and posterior cingulate areas [43].”
From Clinical trials of new drugs for Alzheimer disease (2020) · cites this paper as [43]
In the citing paper
“Studies have shown that amyloid deposition was reduced in all treatment groups at 26 weeks and further reduced by the end of the first year.”
From Clinical trials of new drugs for Alzheimer disease (2020) · cites this paper as [43]
In the citing paper
“Anti-Aβ immunotherapies have shown reductions in amyloid PET and several amyloid reducing therapies for AD use amyloid PET (or CSF) as a key endpoint [172, 173].”
From The use of neuroimaging techniques in the early and differential diagnosis of dementia (2023) · cites this paper as [173]
20 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484
Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide
Haass, C., & Selkoe, D. J. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2101 · Cited by 4,744
Shankar, G. M., Li, S., Mehta, T. H., Garcia-Munoz, A., Shepardson, N. E., Smith, I., Brett, F. M., Farrell, M. A., Rowan, M. J., Lemere, C. A., et al. (2008) · Nature Medicine · doi:10.1038/nm1782 · Cited by 3,685
Villemagne, V. L., Burnham, S., Bourgeat, P., Brown, B., Ellis, K. A., Salvado, O., Szoeke, C., Macaulay, S. L., Martins, R., Maruff, P., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70044-9 · Cited by 2,279
Bard, F., Cannon, C., Barbour, R., Burke, R.-L., Games, D., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., et al. (2000) · Nature Medicine · doi:10.1038/78682 · Cited by 2,012
The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes
Benilova, I., Karran, E., & De Strooper, B. (2012) · Nature Neuroscience · doi:10.1038/nn.3028 · Cited by 1,962
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960
Self-citation
Cited by
Items 201–300 of 1,043
Xiong, M., Jiang, H., Serrano, J. R., Gonzales, E. R., Wang, C., Gratuze, M., Hoyle, R., Bien-Ly, N., Silverman, A. P., Sullivan, P. M., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abd7522 · Cited by 179
Chen, X.-Q., & Mobley, W. C. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00446 · Cited by 175
“Aducanumab, a human monoclonal antibody that selectively targets aggregated Aβ without binding to soluble Aβ monomers, may represent an agent that selectively targets toxic species (Sevigny et al., 2016).”
BackgroundDetection and treatment of Alzheimer’s disease in its preclinical stage
Rafii, M. S., & Aisen, P. S. (2023) · Nature Aging · doi:10.1038/s43587-023-00410-4 · Cited by 160
Amyloid‐β immunotherapy for alzheimer disease: Is it now a long shot?
Panza, F., Lozupone, M., Seripa, D., & Imbimbo, B. P. (2019) · Annals of Neurology · doi:10.1002/ana.25410 · Cited by 178
“A phase Ib, 12-month, double-blind, placebo-controlled, multiple ascending study evaluated intravenous doses from 1 to 10 mg/kg every 4 weeks in 165 Aβ-PET–positive prodromal and mild AD patients.(67) Of the 165 dosed patients, 40 discontinued treatment (24%), most due to adverse events (20 patients) and withdrawal of…”
BackgroundTargeting of nonlipidated, aggregated apoE with antibodies inhibits amyloid accumulation
Liao, F., Li, A., Xiong, M., Bien-Ly, N., Jiang, H., Zhang, Y., Finn, M. B., Hoyle, R., Keyser, J., Lefton, K. B., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci96429 · Cited by 178
“Whether the CD45+ reactive cells are microglia or infiltrating monocytes and to what extent FcR expressed by other cell types in the brain contribute tion via a microglial-mediated clearance mechanism (18, 19).”
BackgroundTargeting Amyloid Aggregation: An Overview of Strategies and Mechanisms
Giorgetti, S., Greco, C., Tortora, P., & Aprile, F. A. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19092677 · Cited by 174
“Squalamine inhibits the aggregation of α-syn by displacing it from the membranes, ** Covalent inhibitors, *** Murine version of BAN2401, **** not taken further.”
BackgroundCummings, J., Ritter, A., & Zhong, K. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-179901 · Cited by 176
Young microglia restore amyloid plaque clearance of aged microglia
Daria, A., Colombo, A., Llovera, G., Hampel, H., Willem, M., Liesz, A., Haass, C., & Tahirovic, S. (2017) · The EMBO Journal · doi:10.15252/embj.201694591 · Cited by 174
“…plaques and reduction in amyloid plaque load have been observed in AD mouse models and humans after A b immunotherapy (Schenk et al , 1999; Bard et al , 2000; Bacskai et al , 2001; Nicoll et al , 2003, 2006; Wilcock et al , 2004; Boche & Nicoll, 2008; Sevigny et al , 2016; Xiang et al , 2016).”
Barakos, J., Purcell, D., Suhy, J., Chalkias, S., Burkett, P., Grassi, C. M., Castrillo-Viguera, C., Rubino, I., & Vijverberg, E. (2022) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2022.21 · Cited by 165
“Higher frequency of ARIA-E among ApoE ε4 carriers has also been observed in clinical studies of gantenerumab, donanemab, lecanemab, and aducanumab (11, 21, 23, 29, 30).”
BackgroundInfluentialBenussi, A., Cantoni, V., Grassi, M., Brechet, L., Michel, C. M., Datta, A., Thomas, C., Gazzina, S., Cotelli, M. S., Bianchi, M., et al. (2022) · Annals of Neurology · doi:10.1002/ana.26411 · Cited by 163
Clinical Research on Alzheimer’s Disease: Progress and Perspectives
Sun, B.-L., Li, W.-W., Zhu, C., Jin, W.-S., Zeng, F., Liu, Y.-H., Bu, X.-L., Zhu, J., Yao, X.-Q., & Wang, Y.-J. (2018) · Neuroscience Bulletin · doi:10.1007/s12264-018-0249-z · Cited by 161
Li, C., Wang, N., Zheng, G., & Yang, L. (2021) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.1c14818 · Cited by 165
The Amyloid Phenomenon and Its Significance in Biology and Medicine
Dobson, C. M., Knowles, T. P. J., & Vendruscolo, M. (2020) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a033878 · Cited by 173
“In addition to small molecules, antibodies are being widely explored in the context of potential therapeutic strategies to combat neurodegenerative conditions (Schenck 2002; Sevigny et al. 2016), and recent work has revealed their ability to inhibit individual steps in the aggregation of specific proteins.”
BackgroundInhibition of miR-331-3p and miR-9-5p ameliorates Alzheimer's disease by enhancing autophagy
Chen, M.-L., Hong, C.-G., Yue, T., Li, H.-M., Duan, R., Hu, W.-B., Cao, J., Wang, Z.-X., Chen, C.-Y., Hu, X.-K., et al. (2021) · Theranostics · doi:10.7150/thno.47408 · Cited by 163
“Neutralization of Aβ by aducanumab showed a promising perspective for the clinical treatment of AD [15, 16].”
BackgroundChen, Y.-A., Lu, C.-H., Ke, C.-C., Chiu, S.-J., Jeng, F.-S., Chang, C.-W., Yang, B.-H., & Liu, R.-S. (2021) · Biomedicines · doi:10.3390/biomedicines9060594 · Cited by 167
Microglial activation states and their implications for Alzheimer's Disease
Valiukas, Z., Tangalakis, K., Apostolopoulos, V., & Feehan, J. (2025) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2024.100013 · Cited by 199
Boyd, R. J., Avramopoulos, D., Jantzie, L. L., & McCallion, A. S. (2022) · Journal of Neuroinflammation · doi:10.1186/s12974-022-02584-x · Cited by 153
“In 2021, the USFDA accelerated approval of the first disease-modifying immunotherapy for AD, Aducanumab—a human monoclonal antibody that selectively targets Aβ aggregates and reduces soluble and insoluble Aβ in a dose-dependent manner [101].”
BackgroundLocal and distant relationships between amyloid, tau and neurodegeneration in Alzheimer's Disease
Iaccarino, L., Tammewar, G., Ayakta, N., Baker, S. L., Bejanin, A., Boxer, A. L., Gorno-Tempini, M. L., Janabi, M., Kramer, J. H., Lazaris, A., et al. (2018) · NeuroImage: Clinical · doi:10.1016/j.nicl.2017.09.016 · Cited by 165
Anti-Amyloid Immunotherapies for Alzheimer's Disease: A 2023 Clinical Update
Yadollahikhales, G., & Rojas, J. C. (2023) · Neurotherapeutics · doi:10.1007/s13311-023-01405-0 · Cited by 154
“The study was limited by a staggered parallelgroup design, small sample sizes, recruitment in a single geographical region (US only), and possible unblinding due to incidence of ARIA [73].”
Background18F-flortaucipir (AV-1451) tau PET in frontotemporal dementia syndromes
Tsai, R. M., Bejanin, A., Lesman-Segev, O., LaJoie, R., Visani, A., Bourakova, V., O’Neil, J. P., Janabi, M., Baker, S., Lee, S. E., et al. (2019) · Alzheimer's Research & Therapy · doi:10.1186/s13195-019-0470-7 · Cited by 164
Amyloid β-protein and beyond: the path forward in Alzheimer’s disease
Walsh, D. M., & Selkoe, D. J. (2020) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2020.02.003 · Cited by 157
Targeting Fyn Kinase in Alzheimer’s Disease
Nygaard, H. B. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.06.004 · Cited by 162
Kim, B., Kim, S., Nam, Y., Park, Y., Shin, S. M., & Moon, M. (2025) · Translational Neurodegeneration · doi:10.1186/s40035-025-00465-w · Cited by 187
Wang, J., Li, Z., Pan, M., Fiaz, M., Hao, Y., Yan, Y., Sun, L., & Yan, F. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114539 · Cited by 161
Passive immunotherapies targeting Aβ and tau in Alzheimer's disease
Plotkin, S. S., & Cashman, N. R. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.105010 · Cited by 155
Withington, C. G., & Turner, R. S. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.862369 · Cited by 148
“Up to 65% of individuals who develop ARIAE continue antibody treatment (19).”
BackgroundSolopova, E., Romero-Fernandez, W., Harmsen, H., Ventura-Antunes, L., Wang, E., Shostak, A., Maldonado, J., Donahue, M. J., Schultz, D., Coyne, T. M., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-43933-5 · Cited by 147
“However, ARIA rates in the clinical trials with aduca-numab were also quite high, despite reports that aducanumab preferentially binds parenchymal versus vascular β -amyloid 24 .”
Alifragis, P., & Marsh, J. (2018) · Neural Regeneration Research · doi:10.4103/1673-5374.230276 · Cited by 153
“For instance, Aβ oligomers are considered to be the toxic species of the peptide (Sevigny et al., 2016), whereas the monomeric form of Aβ is considered to be neutral or even neuroprotective (Giuffrida et al., 2009).”
BackgroundSalloway, S., Honigberg, L. A., Cho, W., Ward, M., Friesenhahn, M., Brunstein, F., Quartino, A., Clayton, D., Mortensen, D., Bittner, T., et al. (2018) · Alzheimer's Research & Therapy · doi:10.1186/s13195-018-0424-5 · Cited by 151
Self-citationControversy and Progress in Alzheimer’s Disease — FDA Approval of Aducanumab
Rabinovici, G. D. (2021) · New England Journal of Medicine · doi:10.1056/nejmp2111320 · Cited by 155
Wahl, D., Solon-Biet, S. M., Cogger, V. C., Fontana, L., Simpson, S. J., Le Couteur, D. G., & Ribeiro, R. V. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104481 · Cited by 144
Rabinovici, G. D., Knopman, D. S., Arbizu, J., Benzinger, T. L. S., Donohoe, K. J., Hansson, O., Herscovitch, P., Kuo, P. H., Lingler, J. H., Minoshima, S., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.14338 · Cited by 205
Self-citationAlbayram, O., Kondo, A., Mannix, R., Smith, C., Tsai, C.-Y., Li, C., Herbert, M. K., Qiu, J., Monuteaux, M., Driver, J., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01068-4 · Cited by 153
Alzheimer’s disease: How metal ions define β-amyloid function
Kepp, K. P. (2017) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2017.05.007 · Cited by 150
The Role of Biomarkers in Alzheimer’s Disease Drug Development
Cummings, J. (2019) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-030-05542-4_2 · Cited by 148
“An example of reduction of fibrillar amyloid in a clinical trial emerged from the trial of the monoclonal antibody aducanumab [68].”
BackgroundThe Important Interface Between Apolipoprotein E and Neuroinflammation in Alzheimer’s Disease
Kloske, C. M., & Wilcock, D. M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00754 · Cited by 152
Delivery of Biologics Across the Blood–Brain Barrier with Molecular Trojan Horse Technology
Pardridge, W. M. (2017) · BioDrugs · doi:10.1007/s40259-017-0248-z · Cited by 152
“The clinical correlate of BBB disruption in patients with AD enrolled in the bapineuzumab clinical trial is amyloid-related imaging abnormalities (ARIA), as detected with magnetic resonance imaging [47].”
BackgroundChen, K. T., Gong, E., de Carvalho Macruz, F. B., Xu, J., Boumis, A., Khalighi, M., Poston, K. L., Sha, S. J., Greicius, M. D., Mormino, E., et al. (2020) · Radiology · doi:10.1148/radiol.2020202527 · Cited by 147
Electromagnetic signatures of the preclinical and prodromal stages of Alzheimer’s disease
Nakamura, A., Cuesta, P., Fernández, A., Arahata, Y., Iwata, K., Kuratsubo, I., Bundo, M., Hattori, H., Sakurai, T., Fukuda, K., et al. (2018) · Brain · doi:10.1093/brain/awy044 · Cited by 151
“Recent disease-modifying clinical trials for Alzheimer’s disease (Sperling et al., 2014; Sevigny et al., 2016) have emphasized the importance of early intervention in the predementia phases, which are categorized as mild cognitive impairment (MCI) and preclinical Alzheimer’s disease stages in the diagnostic criteria o…”
BackgroundRajasekhar, K., & Govindaraju, T. (2018) · RSC Advances · doi:10.1039/c8ra03620a · Cited by 150
UB‐311, a novel UBITh ® amyloid β peptide vaccine for mild Alzheimer's disease
Wang, C. Y., Wang, P., Chiu, M., Finstad, C. L., Lin, F., Lynn, S., Tai, Y., De Fang, X., Zhao, K., Hung, C., et al. (2017) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2017.03.005 · Cited by 150
“Aducanumab in a phase-Ib trial has shown a tantalizing but tenuous evidence that the mAb dose-dependently reduces Ab plaque that correlates with cognitive improvement [46].”
BackgroundReactive astrogliosis: A friend or foe in the pathogenesis of Alzheimer’s disease
Kumar, A., Fontana, I. C., & Nordberg, A. (2023) · Journal of Neurochemistry · doi:10.1111/jnc.15565 · Cited by 150
Amyloid β oligomers (AβOs) in Alzheimer’s disease
Mroczko, B., Groblewska, M., Litman‐Zawadzka, A., Kornhuber, J., & Lewczuk, P. (2017) · Journal of Neural Transmission · doi:10.1007/s00702-017-1820-x · Cited by 160
Cogswell, P. M., Barakos, J. A., Barkhof, F., Benzinger, T. S., Jack, C. R., Poussaint, T. Y., Raji, C. A., Ramanan, V. K., & Whitlow, C. T. (2022) · American Journal of Neuroradiology · doi:10.3174/ajnr.a7586 · Cited by 144
Dimethyl Fumarate Delays Multiple Sclerosis in Radiologically Isolated Syndrome
Okuda, D. T., Kantarci, O. H., Lebrun‐Frénay, C., Sormani, M. P., Azevedo, C. J., Bovis, F., Hua, L. H., Amezcua, L., Mowry, E. M., Hotermans, C., et al. (2022) · Annals of Neurology · doi:10.1002/ana.26555 · Cited by 159
Wu, W., Ji, Y., Wang, Z., Wu, X., Li, J., Gu, F., Chen, Z., & Wang, Z. (2023) · European journal of medical research · doi:10.1186/s40001-023-01512-w · Cited by 168
“Aducanumab is a human mab that selectively targets aggregated forms of Aβ, including soluble oligomers and insoluble fibrils [17].”
BackgroundMethodInfluentialSahoo, A. K., Dandapat, J., Dash, U. C., & Kanhar, S. (2017) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2017.12.015 · Cited by 155
Emerging links between cerebrovascular and neurodegenerative diseases—a special role for pericytes
Lendahl, U., Nilsson, P., & Betsholtz, C. (2019) · EMBO reports · doi:10.15252/embr.201948070 · Cited by 142
Alzheimer's disease: The right drug, the right time
Golde, T. E., DeKosky, S. T., & Galasko, D. (2018) · Science · doi:10.1126/science.aau0437 · Cited by 147
The case for low-level BACE1 inhibition for the prevention of Alzheimer disease
McDade, E., Voytyuk, I., Aisen, P. S. S., Bateman, R. J., Carrillo, M. C., Strooper, B. D., Haass, C., Reiman, E. M., Sperling, R. A., Tariot, P. N., et al. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-021-00545-1 · Cited by 162
The accuracy and robustness of plasma biomarker models for amyloid PET positivity
Benedet, A. L., Brum, W. S., Hansson, O., Initiative, A. D. N., Karikari, T. K., Zimmer, E. R., Zetterberg, H., Blennow, K., & Ashton, N. J. (2022) · Alzheimer's Research & Therapy · doi:10.1186/s13195-021-00942-0 · Cited by 138
Fibrillar Aβ triggers microglial proteome alterations and dysfunction in Alzheimer mouse models
Sebastian Monasor, L., Müller, S. A., Colombo, A. V., Tanrioever, G., König, J., Roth, S., Liesz, A., Berghofer, A., Piechotta, A., Prestel, M., et al. (2020) · eLife · doi:10.7554/elife.54083 · Cited by 147
Copper Toxicity Links to Pathogenesis of Alzheimer’s Disease and Therapeutics Approaches
Ejaz, H. W., Wang, W., & Lang, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21207660 · Cited by 143
“Furthermore, in parallel, antibody-based treatment for Aβ aggregation is now developing and providing safe results as well [337].”
BackgroundSekino, N., Selim, M., & Shehadah, A. (2022) · Journal of Neuroinflammation · doi:10.1186/s12974-022-02464-4 · Cited by 138
“, aducanumab) can slow disease progression in patients with AD [58, 147].”
BackgroundHaass, C., & Selkoe, D. (2022) · PLOS Biology · doi:10.1371/journal.pbio.3001694 · Cited by 145
“Of these antibodies, aducanumab [72] was the first to receive FDA approval [71] but has not yet been approved by the European Medicines Agency (EMA).”
BackgroundFinding useful biomarkers for Parkinson’s disease
Chen-Plotkin, A. S., Albin, R., Alcalay, R., Babcock, D., Bajaj, V., Bowman, D., Buko, A., Cedarbaum, J., Chelsky, D., Cookson, M. R., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aam6003 · Cited by 146
Therapeutic Strategies Targeting Amyloid-β in Alzheimer’s Disease
Pinheiro, L. M. V., & Faustino, C. M. C. (2019) · Current Alzheimer Research · doi:10.2174/1567205016666190321163438 · Cited by 155
Overview of Transgenic Mouse Models for Alzheimer's Disease
Myers, A., & McGonigle, P. (2019) · Current Protocols in Neuroscience · doi:10.1002/cpns.81 · Cited by 142
“…and passive immunization have failed to produce improvements in memory, positron Myers and McGonigle 17 of 21 Current Protocols in Neuroscience emission tomography has confirmed that passive immunization reduces the signal of amyloid binding ligands (Rinne et al., 2010; Sevigny et al., 2016).”
BackgroundDerry, P. J., Hegde, M. L., Jackson, G. R., Kayed, R., Tour, J. M., Tsai, A.-L., & Kent, T. A. (2020) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2019.101716 · Cited by 140
“Second, experimental antibody therapies such as Aducanumab have shown that amyloid plaques can be cleared (Sevigny et al., 2016), though in the case of Aducanumab no therapeutic benefit emerged.”
BackgroundRen, X., Zhao, Y., Xue, F., Zheng, Y., Huang, H., Wang, W., Chang, Y., Yang, H., & Zhang, J. (2019) · Molecular Therapy - Nucleic Acids · doi:10.1016/j.omtn.2019.07.008 · Cited by 138
Mechanisms of protein toxicity in neurodegenerative diseases
Chung, C. G., Lee, H., & Lee, S. B. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2854-4 · Cited by 142
Aprile, F. A., Sormanni, P., Perni, M., Arosio, P., Linse, S., Knowles, T. P. J., Dobson, C. M., & Vendruscolo, M. (2017) · Science Advances · doi:10.1126/sciadv.1700488 · Cited by 145
Iwatsubo, T., Iwata, A., Suzuki, K., Ihara, R., Arai, H., Ishii, K., Senda, M., Ito, K., Ikeuchi, T., Kuwano, R., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.03.009 · Cited by 141
“In view of the continuum in the progression profiles of cognitive and functional decline in mild AD with those of the later stage of LMCI both in J-ADNI and ADNI, the present results may justify the current trend to combine LMCI due to AD (prodromal AD) and mild AD as the target population in clinical trials of DMTs i…”
ResultCurrent and emerging avenues for Alzheimer's disease drug targets
Loera‐Valencia, R., Cedazo‐Minguez, A., Kenigsberg, P. A., Page, G., Duarte, A. I., Giusti, P., Zusso, M., Robert, P., Frisoni, G. B., Cattaneo, A., et al. (2019) · Journal of Internal Medicine · doi:10.1111/joim.12959 · Cited by 141
Zhao, P., Xu, Y., Jiang, L., Fan, X., Li, L., Li, X., Arase, H., Zhao, Y., Cao, W., Zheng, H., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abq0095 · Cited by 141
Lee, M.-C., Yu, W.-C., Shih, Y.-H., Chen, C.-Y., Guo, Z.-H., Huang, S.-J., Chan, J. C. C., & Chen, Y.-R. (2018) · Scientific Reports · doi:10.1038/s41598-018-23122-x · Cited by 134
Xu, M., Mo, X., Huang, H., Chen, X., Liu, H., Peng, Z., Chen, L., Rong, S., Yang, W., Xu, S., et al. (2020) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2020.05.180 · Cited by 137
Ovais, M., Zia, N., Ahmad, I., Khalil, A. T., Raza, A., Ayaz, M., Sadiq, A., Ullah, F., & Shinwari, Z. K. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00284 · Cited by 138
Light‐Induced Chiral Iron Copper Selenide Nanoparticles Prevent β‐Amyloidopathy In Vivo
Zhang, H., Hao, C., Qu, A., Sun, M., Xu, L., Xu, C., & Kuang, H. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.202002028 · Cited by 140
Cathepsin B links oxidative stress to the activation of NLRP3 inflammasome
Bai, H., Yang, B., Yu, W., Xiao, Y. C., Yu, D., & Zhang, Q. (2017) · Experimental Cell Research · doi:10.1016/j.yexcr.2017.11.015 · Cited by 146
Akyol, S., Ugur, Z., Yilmaz, A., Ustun, I., Gorti, S. K. K., Oh, K., McGuinness, B., Passmore, P., Kehoe, P. G., Maddens, M. E., et al. (2021) · Cells · doi:10.3390/cells10102591 · Cited by 134
Cerebrospinal Fluid Biomarkers for Early and Differential Alzheimer’s Disease Diagnosis
Bjerke, M., & Engelborghs, S. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-170680 · Cited by 132
Drug development for alzheimer’s disease: Microglia induced neuroinflammation as a target
Dong, Y., Li, X., Cheng, J., & Hou, L. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030558 · Cited by 136
Roberts, M., Sevastou, I., Imaizumi, Y., Mistry, K., Talma, S., Dey, M., Gartlon, J., Ochiai, H., Zhou, Z., Akasofu, S., et al. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-0884-2 · Cited by 135
Alzheimer's Disease: The Role of Microglia in Brain Homeostasis and Proteopathy
Clayton, K. A., Van Enoo, A. A., & Ikezu, T. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00680 · Cited by 134
“…phenotype that is associated with neurodegeneration that possesses a more exacerbated dystrophic phenotype, but is specifically associated with plaques and dystrophic neurites that cause neurodegeneration. conformational epitope of Aβ, is currently in Phase 3 trials (Sevigny et al., 2016).”
BackgroundWeiner, M. W., Nosheny, R., Camacho, M., Truran‐Sacrey, D., Mackin, R. S., Flenniken, D., Ulbricht, A., Insel, P., Finley, S., Fockler, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.021 · Cited by 134
Strikwerda-Brown, C., Hobbs, D. A., Gonneaud, J., St-Onge, F., Binette, A. P., Ozlen, H., Provost, K., Soucy, J.-P., Buckley, R. F., Benzinger, T. L. S., et al. (2022) · JAMA Neurology · doi:10.1001/jamaneurol.2022.2379 · Cited by 127
Making the final cut: Pathogenic amyloid-β peptide generation by γ-secretase
Steiner, H., Fukumori, A., Tagami, S., & Okochi, M. (2018) · Cell Stress · doi:10.15698/cst2018.11.162 · Cited by 133
“the promising aducanumab antibody that successfully removes patient brain amyloid [165] be beneficial in AD, a combination therapy with Aβ42 production modifiers or C99-selective inhibitors to maintain low amyloid levels, thereby preventing and/or shifting the onset of AD, might be an ideal and more cost-effective str…”
BackgroundThe prion model for progression and diversity of neurodegenerative diseases
Stopschinski, B. E., & Diamond, M. I. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30037-6 · Cited by 142
An exhausted-like microglial population accumulates in aged and APOE4 genotype Alzheimer’s brains
Millet, A., Ledo, J. H., & Tavazoie, S. F. (2024) · Immunity · doi:10.1016/j.immuni.2023.12.001 · Cited by 132
Hey, J. A., Yu, J. Y., Versavel, M., Abushakra, S., Kocis, P., Power, A., Kaplan, P. L., Amedio, J., & Tolar, M. (2018) · Clinical Pharmacokinetics · doi:10.1007/s40262-017-0608-3 · Cited by 129
“Ab oligomers) may produce cognitive and functional benefits in AD patients [5, 6].”
BackgroundNLRP3 inflammasome signalling in Alzheimer's disease
McManus, R. M., & Latz, E. (2024) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.109941 · Cited by 144
“Binding of these antibodies to A β interrupts the amyloid-aggregation process, while also targeting the A β for removal by microglia-mediated phagocytosis (Linse et al., 2020; Sevigny et al., 2016).”
BackgroundIntercellular Spread of Protein Aggregates in Neurodegenerative Disease
Davis, A. A., Leyns, C. E. G., & Holtzman, D. M. (2018) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-100617-062636 · Cited by 131
“Newer-generation antibodies such as aducanumab that bind to plaques and that are being used at higher doses have shown promise in removing plaques and in slowing cognitive decline in early studies (Sevigny et al. 2016).”
BackgroundMicroglia-Mediated Neuroprotection, TREM2, and Alzheimer’s Disease: Evidence From Optical Imaging
Condello, C., Yuan, P., & Grutzendler, J. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.10.007 · Cited by 131
“One of the two domains may be against fibrillar Ab (84), which would lead to enrichment around plaques, providing an approach to engage the second target only in the vicinity of the plaque.”
Ma, M., Gao, N., Li, X., Liu, Z., Pi, Z., Du, X., Ren, J., & Qu, X. (2020) · ACS Nano · doi:10.1021/acsnano.0c02733 · Cited by 131
The amyloid cascade and Alzheimer's disease therapeutics: theory versus observation
Castellani, R. J., Plascencia‐Villa, G., & Perry, G. L. (2019) · Laboratory Investigation · doi:10.1038/s41374-019-0231-z · Cited by 139
Alzheimer’s disease as oligomeropathy
Ono, K. (2018) · Neurochemistry International · doi:10.1016/j.neuint.2017.08.010 · Cited by 129
Aducanumab Therapy to Treat Alzheimer’s Disease: A Narrative Review
Beshir, S. A., Aadithsoorya, A. M., Parveen, A., Goh, S. S. L., Hussain, N., & Menon, V. B. (2022) · International Journal of Alzheimer's Disease · doi:10.1155/2022/9343514 · Cited by 115
“The pharmacokinetics, safety, or tolerability of aducanumab was demonstrated using the following phase I trials: NCT01677572 [18], NCT02782975 [37], NCT01397539 [20], and NCT02434718 [35].”
BackgroundMethodInfluentialInflammatory mechanisms in neurodegeneration
Nichols, M. R., St‐Pierre, M., Wendeln, A., Makoni, N. J., Gouwens, L. K., Garrad, E. C., Sohrabi, M., Neher, J. J., Tremblay, M., & Combs, C. K. (2019) · Journal of Neurochemistry · doi:10.1111/jnc.14674 · Cited by 121
Determining Amyloid-β Positivity Using18F-AZD4694 PET Imaging
Therriault, J., Benedet, A. L., Pascoal, T. A., Savard, M., Ashton, N. J., Chamoun, M., Tissot, C., Lussier, F., Kang, M. S., Bezgin, G., et al. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.120.245209 · Cited by 121
Blood-brain barrier leakage in Alzheimer’s disease: From discovery to clinical relevance
Nehra, G., Bauer, B., & Hartz, A. M. S. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108119 · Cited by 127
Gonzalez-Carter, D., Liu, X., Tockary, T. A., Dirisala, A., Toh, K., Anraku, Y., & Kataoka, K. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2002016117 · Cited by 127
“Such peripheral accumulation limits the clinical translation of therapies by reducing the therapeutic dose reaching the brain and increasing detrimental peripheral side effects (13, 14).”
BackgroundTherapeutic Potential of Secreted Amyloid Precursor Protein APPsα
Mockett, B. G., Richter, M., Abraham, W. C., & Müller, U. C. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00030 · Cited by 115
“, 2014), no disease-modifying treatments have proven effective for clinical use, although there is renewed hope arising from a recent study that has given very promising results from anti-Aβ antibody treatment (Sevigny et al., 2016).”
BackgroundFalck, R. S., Landry, G. J., Best, J. R., Davis, J. C., Chiu, B. K., & Liu-Ambrose, T. Y. L. (2017) · Physical Therapy · doi:10.1093/ptj/pzx074 · Cited by 136
Teter, B., Morihara, T., Lim, G. P., Chu, T., Jones, M. R., Zuo, X., Paul, R. M., Frautschy, S. A., & Cole, G. M. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.02.015 · Cited by 124
“V A A uthor M anuscript V A A uthor M anuscript V A A uthor M anuscript predicting reduced Aβ plaques with potential cognitive benefits in a clinical trial (Sevigny et al., 2016).”
BackgroundProtein condensation diseases: therapeutic opportunities
Vendruscolo, M., & Fuxreiter, M. (2022) · Nature Communications · doi:10.1038/s41467-022-32940-7 · Cited by 137
Alzheimer's disease and late-onset epilepsy of unknown origin: two faces of beta amyloid pathology
Costa, C., Romoli, M., Liguori, C., Farotti, L., Eusebi, P., Bedetti, C., Siliquini, S., Cesarini, E. N., Romigi, A., Mercuri, N. B., et al. (2019) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.09.006 · Cited by 120
Is Alzheimer’s Disease a Liver Disease of the Brain?
Bassendine, M. F., Taylor-Robinson, S. D., Fertleman, M., Khan, M., & Neely, D. (2020) · Journal of Alzheimer's Disease · doi:10.3233/jad-190848 · Cited by 124
Poudel, P., & Park, S. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14040835 · Cited by 124
“This drug is designed to act on the deposition of amyloid-β (Aβ) plaques and neurofibrillary tangles in the brain [6].”
BackgroundAlzheimer's disease failed clinical trials
Asher, S., & Priefer, R. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120861 · Cited by 124
Metadata
- Authors
- Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., O’Gorman, J., Qian, F., Arastu, M., Li, M., Chollate, S., Brennan, M. S., Quintero-Monzon, O., Scannevin, R. H., Arnold, H. M., Engber, T., Rhodes, K., Ferrero, J., Hang, Y., Mikulskis, A., Grimm, J., Hock, C., Nitsch, R. M., & Sandrock, A.
- Affiliations
- Biogen (United States) (US)
- Light Chain Bioscience (Switzerland) (CH)
- Butler Hospital (US)
- University of Zurich (CH)
- Corresponding author
- Sandrock, Alfred
- ORCID
- Venue
- Nature
- Published
- 2016-08-31
- Volume
- 537
- Issue
- 7618
- Pages
- 50-56
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2510806376
- Cited by
- 3,059
- References
- 42
- Citations by year
- 2026: 186 · 2025: 340 · 2024: 389 · 2023: 332 · 2022: 416 · 2021: 326 · 2020: 263 · 2019: 231 · 2018: 268 · 2017: 252 · 2016: 52
- FWCI
- 214.30
- Type
- journal article
- Language
- en
- Update notices
- addendum (2017-06-22)
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion)
- Funders
- Biogen
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- aducanumab, Alzheimer's disease, amyloid plaques, anti-amyloid monoclonal antibodies, immunotherapy, amyloid hypothesis, transgenic mouse model, prodromal Alzheimer's disease, clinical deterioration, amyloid-related imaging abnormalities, drug safety and tolerability
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Amyloid, Animals, Brain, Disease Models, Animal, Dose-Response Relationship, Drug, Female, Humans, Male, Mice, Transgenic, Middle Aged, Models, Biological, Solubility, Amyloid beta-Peptides, Clinical Trials, Phase III as Topic, Mice, Plaque, Amyloid, Antibodies, Monoclonal, Humanized, Protein Aggregation, Pathological
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.